Cargando…
Surgical ablation for atrial fibrillation: impact of Diabetes Mellitus type 2
BACKGROUND: Diabetes mellitus (DM) type 2 is an independent risk factor for atrial fibrillation (AF). Surgical ablation or "maze procedure" is an option for patients with AF undergoing concomitant or isolated cardiac surgery. The aim of this study was to evaluate the impact of DM type 2 on...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067240/ https://www.ncbi.nlm.nih.gov/pubmed/37004023 http://dx.doi.org/10.1186/s12933-023-01810-x |
_version_ | 1785018423798923264 |
---|---|
author | Kogan, Alexander Grupper, Avishay Sabbag, Avi Ram, Eilon Jamal, Tamer Nof, Eyal Fisman, Enrique Z. Levin, Shany Beinart, Roy Frogel, Jonathan Raanani, Ehud Sternik, Leonid |
author_facet | Kogan, Alexander Grupper, Avishay Sabbag, Avi Ram, Eilon Jamal, Tamer Nof, Eyal Fisman, Enrique Z. Levin, Shany Beinart, Roy Frogel, Jonathan Raanani, Ehud Sternik, Leonid |
author_sort | Kogan, Alexander |
collection | PubMed |
description | BACKGROUND: Diabetes mellitus (DM) type 2 is an independent risk factor for atrial fibrillation (AF). Surgical ablation or "maze procedure" is an option for patients with AF undergoing concomitant or isolated cardiac surgery. The aim of this study was to evaluate the impact of DM type 2 on early and long-term outcomes of patients following surgical AF ablation. METHODS: We performed an observational cohort study in Israel’s largest tertiary care center. All data of patients who underwent surgical AF ablation, between 2006 and 2021 were extracted from our departmental database. Patients were divided into Group I (non-diabetic patients) and Group II (DM type 2 patients). We compared the two groups with respect to freedom from recurrent atrial arrhythmia, and mortality rate. RESULTS: The study population included 606 patients. Group I (non-DM patients), consisting of 484 patients, and Group II (DM type 2 patients), comprised 122 patients. Patients with DM were older, had more hypertension and incidence of cerebrovascular accident (CVA)/transient ischemic attack (TIA), higher EuroSCORE (p < .05 for all), and a longer bypass time—130 ± 40 vs. 122 ± 36 min (p = 0.028). The mean follow-up duration was 39.0 ± 22.7 months. Freedom from atrial fibrillation was similar between the non-DM and DM type 2 groups after a 1-year follow-up, 414 (88.2%) vs. 101 (87.1%) (p = 0.511), after a 3-year follow-up, 360 (86.3%) vs. 84 (79.9%) (p = 0.290) and after a 5-year follow-up, 226 (74.1%) vs. 55 (71.5%) (p = 0.622) respectively. Furthermore, 1- and 3-year mortality was similar between non-DM and DM type 2 groups, 2.5% vs. 4.9%, (p = 0.226) and 5.6% vs. 10.5% (p = 0.076) respectively. 5-year mortality was higher in Group II (DM type 2 patients) compared with Group I (non-DM patients), 11.1% vs. 23.4% (p = 0.009). CONCLUSION: Surgical ablation had a high success rate, with freedom from recurrent atrial arrhythmia at 1- 3- and 5- years follow-up in both the DM type 2 and non-DM groups. Furthermore,1- and 3-year mortality after surgical ablation was also similar in both groups. However, 5-year mortality was higher in the DM type 2 group. |
format | Online Article Text |
id | pubmed-10067240 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-100672402023-04-03 Surgical ablation for atrial fibrillation: impact of Diabetes Mellitus type 2 Kogan, Alexander Grupper, Avishay Sabbag, Avi Ram, Eilon Jamal, Tamer Nof, Eyal Fisman, Enrique Z. Levin, Shany Beinart, Roy Frogel, Jonathan Raanani, Ehud Sternik, Leonid Cardiovasc Diabetol Research BACKGROUND: Diabetes mellitus (DM) type 2 is an independent risk factor for atrial fibrillation (AF). Surgical ablation or "maze procedure" is an option for patients with AF undergoing concomitant or isolated cardiac surgery. The aim of this study was to evaluate the impact of DM type 2 on early and long-term outcomes of patients following surgical AF ablation. METHODS: We performed an observational cohort study in Israel’s largest tertiary care center. All data of patients who underwent surgical AF ablation, between 2006 and 2021 were extracted from our departmental database. Patients were divided into Group I (non-diabetic patients) and Group II (DM type 2 patients). We compared the two groups with respect to freedom from recurrent atrial arrhythmia, and mortality rate. RESULTS: The study population included 606 patients. Group I (non-DM patients), consisting of 484 patients, and Group II (DM type 2 patients), comprised 122 patients. Patients with DM were older, had more hypertension and incidence of cerebrovascular accident (CVA)/transient ischemic attack (TIA), higher EuroSCORE (p < .05 for all), and a longer bypass time—130 ± 40 vs. 122 ± 36 min (p = 0.028). The mean follow-up duration was 39.0 ± 22.7 months. Freedom from atrial fibrillation was similar between the non-DM and DM type 2 groups after a 1-year follow-up, 414 (88.2%) vs. 101 (87.1%) (p = 0.511), after a 3-year follow-up, 360 (86.3%) vs. 84 (79.9%) (p = 0.290) and after a 5-year follow-up, 226 (74.1%) vs. 55 (71.5%) (p = 0.622) respectively. Furthermore, 1- and 3-year mortality was similar between non-DM and DM type 2 groups, 2.5% vs. 4.9%, (p = 0.226) and 5.6% vs. 10.5% (p = 0.076) respectively. 5-year mortality was higher in Group II (DM type 2 patients) compared with Group I (non-DM patients), 11.1% vs. 23.4% (p = 0.009). CONCLUSION: Surgical ablation had a high success rate, with freedom from recurrent atrial arrhythmia at 1- 3- and 5- years follow-up in both the DM type 2 and non-DM groups. Furthermore,1- and 3-year mortality after surgical ablation was also similar in both groups. However, 5-year mortality was higher in the DM type 2 group. BioMed Central 2023-03-31 /pmc/articles/PMC10067240/ /pubmed/37004023 http://dx.doi.org/10.1186/s12933-023-01810-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Kogan, Alexander Grupper, Avishay Sabbag, Avi Ram, Eilon Jamal, Tamer Nof, Eyal Fisman, Enrique Z. Levin, Shany Beinart, Roy Frogel, Jonathan Raanani, Ehud Sternik, Leonid Surgical ablation for atrial fibrillation: impact of Diabetes Mellitus type 2 |
title | Surgical ablation for atrial fibrillation: impact of Diabetes Mellitus type 2 |
title_full | Surgical ablation for atrial fibrillation: impact of Diabetes Mellitus type 2 |
title_fullStr | Surgical ablation for atrial fibrillation: impact of Diabetes Mellitus type 2 |
title_full_unstemmed | Surgical ablation for atrial fibrillation: impact of Diabetes Mellitus type 2 |
title_short | Surgical ablation for atrial fibrillation: impact of Diabetes Mellitus type 2 |
title_sort | surgical ablation for atrial fibrillation: impact of diabetes mellitus type 2 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067240/ https://www.ncbi.nlm.nih.gov/pubmed/37004023 http://dx.doi.org/10.1186/s12933-023-01810-x |
work_keys_str_mv | AT koganalexander surgicalablationforatrialfibrillationimpactofdiabetesmellitustype2 AT grupperavishay surgicalablationforatrialfibrillationimpactofdiabetesmellitustype2 AT sabbagavi surgicalablationforatrialfibrillationimpactofdiabetesmellitustype2 AT rameilon surgicalablationforatrialfibrillationimpactofdiabetesmellitustype2 AT jamaltamer surgicalablationforatrialfibrillationimpactofdiabetesmellitustype2 AT nofeyal surgicalablationforatrialfibrillationimpactofdiabetesmellitustype2 AT fismanenriquez surgicalablationforatrialfibrillationimpactofdiabetesmellitustype2 AT levinshany surgicalablationforatrialfibrillationimpactofdiabetesmellitustype2 AT beinartroy surgicalablationforatrialfibrillationimpactofdiabetesmellitustype2 AT frogeljonathan surgicalablationforatrialfibrillationimpactofdiabetesmellitustype2 AT raananiehud surgicalablationforatrialfibrillationimpactofdiabetesmellitustype2 AT sternikleonid surgicalablationforatrialfibrillationimpactofdiabetesmellitustype2 |